MedTrace Logo

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

NCT02903160 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-02-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer. The hypothesis is that the identification of optimal combinations and sequencing of therapies can help prevent or delay the development of therapeutic drug resistance, and can be safely tolerated.

Conditions

Interventions

DRUG

Abiraterone acetate

Abiraterone acetate 1000 mg PO daily

DRUG

Prednisone

5 mg PO twice a day

DRUG

Radium-223 dichloride

50 kBq/kg IV monthly

DRUG

cabazitaxel

25 mg/m2 IV every 3 weeks

DRUG

Carboplatin

Carboplatin AUC 4 IV every 3 weeks

DRUG

Enzalutamide

160 mg PO daily

Sponsors & Collaborators

Principal Investigators

  • Bobby Liaw, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-13
Primary Completion
2021-11-15
Completion
2021-11-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02903160 on ClinicalTrials.gov